The Center for Biosimilars® recaps the top 5 stories in biosimilars news for the week of November 13.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of November 13.
Number 5: Intragovernmental organization The South Centre has released a paper that calls on regulatory bodies to approve “biological generics” rather than biosimilars.
Number 4: At the SMi Biosimilars North America 2017 conference, a Mylan executive warned that reference product sponsors may be involved in a “whisper campaign” against biosimilars.
Number 3: A recent review identified patient-, disease-, and treatment-related factors that may predict response to anti—tumor necrosis factor therapies.
Number 2: Contributor Sonia T. Oskouei breaks down the key facts that biosimilar stakeholders need to know about CMS’ recent change in biosimilar reimbursement policy.
Number 1: Two major biosimilar patent litigation cases came to a close in recent days, with the ruling Amgen v Apotex upheld in an appellate court, and with Janssen dropping its suit against biosimilar developer Samsung Bioepis.
To read all of these articles and more, visit centerforbiosimilars.com.
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 27th 2023As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).